Precision oncology: A primer for pediatric surgeons from the APSA cancer committee.

摘要: Although most children with cancer can be cured of their disease, a subset patients adverse tumor types or biological features, and those relapsed refractory disease have significantly worse prognosis. Furthermore, current cytotoxic therapy is associated significant late effects. Precision oncology, using molecular therapeutics targeted against unique genetic features the patient's tumor, offers potential to transform multimodal for these patients. Potentiated by advances in sequencing technology therapeutic development, accelerated large-scale multi-institutional basket trials, field pediatric precision oncology has entered mainstream. These novel important implications surgical decision making, as well pre- postoperative care. This review summarizes state medicine including active North American European clinical trials. LEVEL OF EVIDENCE: Treatment study Level V.